Gossamer Bio
GOSS
Gossamer Bio (GOSS) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$13.60
- EPS estimate
- −$14.17
- EPS surprise
- +4.03%
- Revenue surprise
- +112.41%
- Revenue
- $11.5M
- Revenue estimate
- $5.4M
- Reported
- Aug 5, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 5, 2025 | −$14.17 | −$13.60 | +4.03% | $11.5M | SEC |
| Q1 2025 | May 15, 2025 | −$14.97 | −$12.80 | +14.50% | $9.9M | SEC |
| Q4 2024 | Mar 13, 2025 | −$13.60 | −$12.00 | +11.76% | $9.4M | SEC |
| Q3 2024 | Nov 7, 2024 | −$11.77 | −$11.20 | +4.86% | $9.5M | SEC |
| Q2 2024 | Aug 12, 2024 | $40.53 | $17.60 | −56.58% | $95.8M | SEC |
| Q1 2024 | May 7, 2024 | −$15.21 | −$15.20 | +0.05% | $0.00 | SEC |
| Q4 2023 | Mar 5, 2024 | −$16.67 | −$16.80 | −0.80% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$20.52 | −$16.80 | +18.11% | $0.00 | SEC |
| Q2 2023 | Aug 8, 2023 | −$39.14 | −$36.00 | +8.02% | $0.00 | SEC |
| Q1 2023 | May 9, 2023 | −$42.40 | −$41.60 | +1.89% | $0.00 | SEC |
| Q4 2022 | Mar 17, 2023 | −$49.84 | −$47.20 | +5.29% | $0.00 | SEC |
| Q3 2022 | Nov 3, 2022 | −$51.42 | −$52.00 | −1.12% | $0.00 | SEC |
| Q2 2022 | Aug 9, 2022 | −$55.28 | −$59.20 | −7.09% | $0.00 | SEC |
| Q1 2022 | May 10, 2022 | −$61.29 | −$60.80 | +0.79% | $0.00 | SEC |
| Q4 2021 | Mar 3, 2022 | −$60.10 | −$59.20 | +1.50% | $0.00 | SEC |
| Q3 2021 | Nov 8, 2021 | −$62.80 | −$64.00 | −1.91% | $0.00 | SEC |
| Q2 2021 | Aug 9, 2021 | −$60.64 | −$64.00 | −5.54% | $0.00 | SEC |
| Q1 2021 | May 6, 2021 | −$60.48 | −$62.40 | −3.17% | $0.00 | — |
| Q4 2020 | Feb 25, 2021 | −$63.20 | −$70.40 | −11.39% | $0.00 | SEC |
| Q3 2020 | Nov 10, 2020 | −$68.27 | −$64.00 | +6.25% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Gossamer Bio (GOSS) last report earnings?
Gossamer Bio last reported on Aug 5, 2025, covering fiscal Q2 2025.
Did GOSS beat earnings estimates?
Yes. Gossamer Bio reported EPS of −$13.60 for Q2 2025 against a −$14.17 estimate — a 4.03% beat.
How much revenue did GOSS report last quarter?
Gossamer Bio reported $11.5M in revenue for Q2 2025, against a consensus estimate of $5.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.